G1 Therapeutics

Real-time Quotes | Nasdaq Last Sale

After Hours: 18.46 0 0.00% 17:51 12/04 EST
Corp Actions
Sundial Growers, FSD Pharma leads healthcare gainers; SCWorx, 9 Meters Biopharma among major losers
Gainers: Sundial Growers (SNDL) +35%, FSD Pharma (HUGE) +32%, Apollo Endosurgery (APEN) +26%, G1 Therapeutics (GTHX) +23%, Oncolytics Biotech (ONCY) +17%.Losers: SCWorx (WORX) -14%, 9 Meters Biopharma (NMTR) -14%, AnPac Bio-Medical Science (ANPC) -11%, Synlogic (SYBX) -11%, Spruce Biosciences (SPRB) -10%.
Seekingalpha · 4d ago
Return On Capital Employed Overview: G1 Therapeutics
During Q3, G1 Therapeutics (NASDAQ: GTHX) brought in sales totaling $26.60 million. However, earnings decreased 68.38%, resulting in a loss of $9.74 million. G1 Therapeutics collected $2.14 million in revenue during Q2, but reported earnings showed a $30.82 million loss.What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, G1 Therapeutics posted an ROCE of -0.05%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on GTHXROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows G1 Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In G1 Therapeutics's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Insight G1 Therapeutics reported Q3 earnings per share at $-0.31/share, which did not meet analyst predictions of $-0.3/share.See more from Benzinga * Click here for options trades from Benzinga * ROCE Insights For China Automotive Systems * 5 Value Stocks To Watch In The Communication Services Sector(C) 2020 Benzinga does not provide investment advice. All rights reserved.
Benzinga · 4d ago
Mid-Morning Market Update: Markets Open Lower; S&P Global To Buy IHS Markit For $44B
Following the market opening Monday, the Dow traded down 0.95% to 29,626.44 while the NASDAQ fell 0.12% to 12,190.71. The S&P also fell, dropping 0.40% to 3,623.96.
Benzinga · 5d ago
Thinking about trading options or stock in Tesla, G1 Therapeutics, Apple, Micron Technology, or At Home Group?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, GTHX, AAPL, MU, and HOME.
PR Newswire - PRF · 5d ago
MRNA, GME, GNW and QS among premarket gainers
Sunesis Pharmaceuticals (SNSS) +50% after announcing merger agreement with Viracta Therapeutics.China Automotive Systems (CAAS) +32% on guiding 2021 sales boom.India Globalization Capital (IGC) +24%.Ameri Holdings (AMRH) +26%.Oramed Pharmaceuticals (ORMP) +24%.Navios Maritime Holdings (NM) +20%.Genworth Financial
Seekingalpha · 5d ago
Billionaire Israel Englander Pours Money Into 2 Strong Buy Stocks
Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career interning at investment firm Oppenheimer, later going on to purchase a seat on the American Stock Exchange, where he would serve as a floor broker, trader and specialist.In 1989, along with Ronald Shear, Englander founded hedge fund Millennium Management. As evidence of his stellar track record, the guru took the $35 million the fund was started with and turned it into over $40 billion in assets under management. With his personal net worth clocking in at $7.2 billion, it’s no wonder Wall Street pays attention when Englander makes a move.Bearing this in mind, our focus shifted to Millenium’s most recent 13F filing, which discloses the stocks the fund snapped up in the third quarter. Locking in on two tickers in particular, TipRanks’ database revealed that both names score a “Strong Buy” analyst consensus. What’s more, the analyst community sees massive upside potential in store for each.G1 Therapeutics (GTHX)Bringing a deep understanding of the biology of cancer and extensive drug discovery experience to the table, G1 Therapeutics works to develop therapies that could potentially improve the lives of patients battling the deadly disease. Ahead of a key regulatory decision, the Street is pounding the table on this name.During the third quarter, Englander and Millennium picked up a new stake in GTHX. Pulling the trigger on 555,937 shares, the value of the holding comes in at $6,421,000.Turning to the analyst community, Needham’s Chad Messer tells clients that he has high hopes ahead of the February 15 PDUFA date for trilaciclib, its therapy designed to improve outcomes for cancer patients treated with chemotherapy. The therapy’s NDA was accepted in August for Priority Review based on results from three randomized clinical studies in small cell lung cancer (SCLC), with the FDA indicating that it doesn’t plan on holding an advisory committee (AdComm) meeting.As trilaciclib is the first CDK4/6 inhibitor to be used to treat chemo-induced bone marrow toxicity, Messer argues that the lack of an AdComm is “meaningful.” Expounding on this, he stated, “We believe this reflects the agency's appreciation of the unmet need, comfort with the safety profile of the CDK4/6 class, and efficacy profile of trilaciclib.”GTHX will also focus on the inclusion of trilaciclib into NCCN guidelines. It should also be noted that a Phase 3 pivotal study evaluating the candidate in metastatic colorectal cancer (mCRC) is set to kick off by year end.Adding to the good news, GTHX and its partner, Boehringer Ingelheim, are preparing for the commercial launch of trilaciclib, with the companies covering approximately 2,500 treating oncologists and providing educational materials regarding the use of trilaciclib ahead of treatment and the benefits of multi-lineage preservation.If that wasn’t enough, the rintodestrant (its selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER+) breast cancer) plus palbociclib combination study was able to wrap up enrollment earlier than expected, reflecting “the appeal of an all-oral treatment regimen during a global pandemic,” in Messer’s opinion. With a data readout slated for Q2 2021, the analyst believes a “positive readout could prove to be a significant value driver.”In line with his optimistic approach, Messer reiterated a Buy rating and $74 price target, indicating 417% upside potential. (To watch Messer’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 3 to be exact, have been issued in the last three months. Therefore, the message is clear: GTHX is a Strong Buy. Given the $59 average price target, shares could rise 312% in the next year. (See GTHX stock analysis on TipRanks)Epizyme (EPZM)Also fighting the good fight against cancer, as well as against other serious diseases, Epizyme wants to find new treatments through novel epigenetic medicines. Even though the company faces headwinds with regard to its recent product launch, several members of the Street believe big things are in store.Millenium purchased 461,258 shares during the third quarter, with the buy reflecting a new position for the hedge fund. As for the value of the holding, it lands at $5,503,000.Writing for Wedbush, 5-star analyst David Nierengarten points out that the pandemic has limited oncologist visits, and therefore, Tazverik (the company's follicular lymphoma treatment) sales were lower than he expected. He points out that “the pandemic shifts the launch curve to an ‘incidence model’ rather than a prevalence model, as there is a limited patient pool to draw from if they are delaying office visits,” with patients waiting to seek treatment until they experience symptoms of progression.Additionally, although the launch is virtual and physician awareness is high, physicians are opposed to prescribing a new medication without examining the patient in person. That being said, Nierengarten remains optimistic about the therapy.“Despite these headwinds, Tazverik came close to meeting our estimates, and it is gaining market share, including seeing initial sales in second line. We expect more meaningful second line sales to begin in 2021, and have more gradually incorporated them into our launch curve,” the analyst explained.When it comes to the time on therapy, Nierengarten argues it’s too early to come to any conclusions. However, he highlights the fact that durability of response was relatively long and patients were treated past progression in the registration study. “Furthermore, the headwind against switching therapies turns into a tailwind of Tazverik maintenance once a patient is on therapy. This will likely contribute more meaningfully to 2H21 revenues and potential revenue outperformance,” he added.Summing it all up, Nierengarten commented, “At current levels, we believe investors are too negative on Tazverik’s potential and patience should be rewarded.”Based on all of the above, Nierengarten sides with the bulls, reiterating an Outperform rating and $27 price target. This target conveys his confidence in EPZM’s ability to climb 122% higher in the next year. (To watch Nierengarten’s track record, click here)Most other analysts echo Nierengarten’s sentiment. 3 Buys and 1 Hold add up to a Strong Buy consensus rating. With an average price target of $23.25, the upside potential comes in at 91%. (See EPZM stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 5d ago
G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020
G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3 Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET.
GlobeNewswire · 11/24 12:00
G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020
RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET. To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website.About G1 Therapeutics G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics.Contact: Jeff Macdonald G1 Therapeutics, Inc. Senior Director, Investor Relations & Corporate Communications 919-907-1944
GlobeNewswire · 11/24 12:00
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GTHX. Analyze the recent business situations of G1 Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GTHX stock price target is 50.00 with a high estimate of 82.00 and a low estimate of 21.00.
Institutional Holdings
Institutions: 165
Institutional Holdings: 34.82M
% Owned: 91.51%
Shares Outstanding: 38.05M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/Independent Director
Garry Nicholson
President/Chief Executive Officer/Director
Mark Velleca
Chief Financial Officer
Jennifer Moses
Chief Operating Officer
Terry Murdock
Senior Vice President
Rajesh Malik
Chief Scientific Officer
Jay Strum
General Counsel/Secretary
James Hanson
Mark Avagliano
Soma Gupta
Independent Director
John Bailey
Independent Director
Willie Deese
Independent Director
Fredric Eshelman
Jack Bailey
Independent Director
fredric Eshelman
Independent Director
Glenn Muir
Independent Director
Seth Rudnick
Independent Director
Cynthia Schwalm
Independent Director
Andrew Witty
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GTHX
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Hot Stocks

Webull offers kinds of G1 Therapeutics Inc stock information, including NASDAQ:GTHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GTHX stock methods without spending real money on the virtual paper trading platform.